Abbott Reports 14.4 Percent Sales Growth in Third Quarter

AbbottWorldwide Pharmaceutical Sales Increased 19.6 Percent. Worldwide Medical Products Sales Increased 12.0 Percent. International Nutritionals Sales Increased 15.6 Percent. Company Confirms Earnings-Per-Share Outlook for 2007 and 2008.

Abbott announced financial results for the third quarter ended September 30, 2007.

  • Diluted earnings per share, excluding specified items, were $0.67, above Abbott's previously announced guidance range of $0.64 to $0.66. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.46.
  • Based on its strong results year to date, Abbott is confirming its 2007 earnings-per-share outlook and raising the lower end of its previous guidance range. In addition, the company is confirming its outlook for an accelerating rate of earnings-per-share growth in 2008 compared to 2007.
  • Worldwide sales increased 14.4 percent to $6.4 billion, including a favorable 2.8 percent effect of exchange rates.
  • U.S. pharmaceutical sales increased 17.5 percent and International pharmaceutical sales increased 22.2 percent, driven by double-digit growth in HUMIRA®, Kaletra® and TriCor®, and included $167 million of Niaspan® sales. Based on the continued strong sales performance of HUMIRA, which contributed more than $800 million in worldwide sales in the third quarter, Abbott estimates 2007 global sales of $3 billion.
  • Worldwide medical products sales increased 12.0 percent, driven by 13.8 percent growth in worldwide Diabetes Care sales, 14.9 percent growth worldwide in Abbott Vascular, and 14.4 percent growth in International diagnostics sales.
  • Worldwide nutritional products sales were led by 15.6 percent growth in International nutritionals, with continued strong performance in key emerging growth markets.
  • "Abbott's strong performance this quarter was again balanced across our major broad-based businesses," said Miles D. White, chairman and chief executive officer, Abbott. "We expect this momentum to continue in the fourth quarter and into 2008, when the strength of our diversity will drive an accelerating rate of earnings-per-share growth compared to 2007."

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...